Betalain- and betacyanin-rich supplements’ impacts on the PBMC SIRT1 and LOX1 genes expression and Sirtuin-1 protein levels in coronary artery disease patients: A pilot crossover clinical trial

SummaryThe aim of this study was to determine whether complement C3 is an indicator of coronary artery disease (CAD). We measured plasma C3 and CRP levels in 278 patients undergoing coronary angiography for typical symptoms of CAD and 269 healthy age and sex matched controls. C3 levels were significantly higher in patients compared with controls (1.15 g/l and 0.92 g/l respectively; p<0.001). In the patient group, C3 levels correlated with BMI, fasting glucose, HbA1c, fibrinogen, CRP and HDL in both men and women. CRP levels were also higher in patients compared with controls (1.14 mg/l and 0.86 mg/l respectively; p=0.005) and correlated with markers of the metabolic syndrome. In a logistic regression model including C3, smoking, hypertension, cholesterol and diabetes, C3 was independently associated with CAD with an odds ratio of 3.20 for a 1 SD increase in C3 levels. In contrast, CRP was not independently associated with CAD in a similar regression analysis. In conclusion, both C3 and CRP plasma levels are elevated in patients with symptoms of CAD. However, C3 seems to be a better indicator of CAD than CRP in this study, suggesting that C3 could be an additional marker for risk stratification in atherosclerosis.

Download Full-text

Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease

European Heart Journal ◽

10.1093/eurheartj/ehi356 ◽

2005 ◽

Vol 26 (20) ◽

pp. 2099-2105 ◽

Cited By ~ 38

Author(s):

Fabrizio Tomai ◽

Flavio Ribichini ◽

Anna S. Ghini ◽

Valeria Ferrero ◽

Giuseppe Andò ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Microvascular Dysfunction ◽

Coronary Microvascular Dysfunction ◽

C Reactive Protein ◽

Protein Levels ◽

Reactive Protein ◽

Artery Disease

Download Full-text

The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: A secondary analysis of a randomized clinical trial

Journal of Clinical Lipidology ◽

10.1016/j.jacl.2018.03.080 ◽

2018 ◽

Vol 12 (4) ◽

pp. 937-947.e2 ◽

Cited By ~ 5

Author(s):

Abdulhamied Alfaddagh ◽

Tarec K. Elajami ◽

Mohamad Saleh ◽

Mohamad Elajami ◽

Bruce R. Bistrian ◽

...

Keyword(s):

Coronary Artery Disease ◽

Clinical Trial ◽

Coronary Artery ◽

Physical Function ◽

Randomized Clinical Trial ◽

Joint Replacement ◽

Secondary Analysis ◽

Artery Disease ◽

Docosahexaenoic Acids

Download Full-text

Antibodies to N-homocysteinylated albumin as a marker for earlyonset coronary artery disease in men

Thrombosis and Haemostasis ◽

10.1160/th04-08-0493 ◽

2005 ◽

Vol 93 (02) ◽

pp. 346-350 ◽

Cited By ~ 40

Author(s):

Anetta Undas ◽

Milosz Jankowski ◽

Magdalena Twardowska ◽

Agnieszka Padjas ◽

Hieronim Jakubowski ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Multivariate Logistic Regression Analysis ◽

Mthfr C677t ◽

Serum Levels ◽

Autoimmune Response ◽

Mthfr C677t Polymorphism ◽

Protein Levels ◽

Reactive Protein ◽

Artery Disease

Summary N-homocysteinylated (Nε-Hcy) proteins and corresponding antibodies have recently been discovered in humans and animals. Increased autoimmune response to Nε -Hcy-proteins has been reported in stroke patients. The aim of the present study was to investigate whether antibodies against N-homocysteinylated albumin are associated with coronary artery disease (CAD).We studied 88 male patients aged 50 years or under with angiographically documented CAD and 100 age-matched apparently healthy men as controls. Serum levels of IgG antibodies against Nε-Hcy-albumin were determined using an enzymelinked immunosorbent assay. Seropositivity to anti-Nε -Hcy-albumin antibodies was 5-fold more frequent in CAD patients than in controls (52.3 % vs 10.0 %; p<0.0001). Plasma Hcy levels in CAD patients were also significantly higher in the former than in the latter group (medians, 13.0 μ M vs 12.1 μ M; p=0.026). Importantly, 41.2% of subjects with plasma total Hcy >14.5 mM were seropositive compared with 25.5 % of normohomocysteinemic individuals (p=0.048).There was a weak correlation between anti-Nε-Hcy-albumin antibodies and Hcy levels (r=0.16; p=0.03). By multivariate logistic regression analysis, seropositivity to anti-Nε-Hcy-albumin antibodies was an independent predictor of early CAD (OR, 14.82; 95% CI, 4.47 to 49.19; p=0.00002). Interestingly, anti-Nε-Hcy-albumin antibodies were associated with C-reactive protein levels (r=0.24; p=0.002). Seropositivity to anti-Nε-Hcy-albumin antibodies showed no association with the MTHFR C677T polymorphism. Our results suggest that seropositivity to antibodies against Nε-homocysteinylated albumin is associated with early-onset CAD. An autoimmune response to Nε-Hcy-albumin may represent a novel mechanism involved in the early development of CAD.

Download Full-text

P2722Optimizing diagnosis of obstrutive coronary artery disease by CT angiography and ischemia test: a randomized clinical trial

European Heart Journal ◽

10.1093/eurheartj/ehz748.1039 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

J P Dias Ferreira Reis ◽

R Ramos ◽

P Modas Daniel ◽

S Rosa Aguiar ◽

L Almeida Morais ◽

...

Keyword(s):

Coronary Artery Disease ◽

Clinical Trial ◽

Coronary Artery ◽

Coronary Angiography ◽

Invasive Coronary Angiography ◽

Computed Tomographic Angiography ◽

Functional Test ◽

Computed Tomographic ◽

Artery Disease ◽

Tomographic Angiography

Abstract Aim In patients with suspected coronary artery disease (CAD), computed tomographic angiography (CTA) may improve patient selection for invasive coronary angiography (ICA) as alternative to functional testing. However, the role of CTA in symptomatic patients after abnormal functional test is incompletely defined. Methods and results This randomized clinical trial conducted in single academic tertiary center selected 218 symptomatic patients (pts) with mild to moderately abnormal functional test referred to invasive coronary to receive either the originally intended ICA (n=103) or CTA (n=115). CTA interpretation and subsequent care decisions were made by the clinical team. Patients with high risk features on functional tests, previous acute coronary syndrome, previously documented CAD, chronic kidney disease (GFR <60 ml/min/1.73m2) or persistent atrial fibrillation were excluded. The primary endpoint was the percentage of ICA with no significant obstructive CAD (no stenosis ≥50%) in each group. Diagnostic and revascularization yields of ICA in either group were also assessed. Subjects averaged 68±9 years of age, 60% were male, 29% were diabetic. Nuclear perfusion stress test was used in 33.9% in CTA group and 31.1% in control group (p=0.655). Mean post (functional) test probability of obstructive CAD was 34%. Overall prevalence of obstructive CAD was 32.1%. In the CTA group, ICA angiography was cancelled by referring physicians in 83 of the pts (72.2%) after receiving CTA results. For those undergoing ICA, nonobstructive CAD was found in 5 pts (15.6%) in the CTA-guided arm and 60 (58.3%) in the usual care arm (P<0.001). Mean cumulative radiation exposure related to diagnostic work up was similar in both groups (6±14 vs 5±14mSv, P=0.152), but a greater cumulative contrast dose in the CTA-guided group (87.5±21 vs 77±40, p=0.026) was observed. Both diagnostic (84.4% vs 41.7, p<0.001) and revascularization (71.9% vs 38.8%, p=0.001) yields were significantly higher for CTA-guided ICA as compared to standard functional test-guided ICA. Conclusions In patients with suspected CAD and mild to moderately abnormal functional test, a diagnostic strategy including computed tomographic angiography as gatekeeper is effective and significantly improves diagnostic and revascularization yields of invasive coronary angiography.

Download Full-text